Jeff Durrbeck, President of Odne Inc., is proud to announce the appointment of Joe Werner as Director of Strategic Accounts. With over 20 years of experience in the dental industry, Joe brings a wealth of expertise in key areas such as Key Opinion Leader (KOL) development, endodontics, relationship management and navigating the dynamic landscape of Dental Service Organizations (DSOs).
Joe Werner, Director of Strategic Accounts, Odne Inc.
Joe is an essential addition to Odne’s training and sales team, especially with the upcoming AAE Annual Meeting (April 17-20, 2024, Los Angeles), where Odne will launch its Priority Access Program to the endodontic community. “Joe’s dedication to advancing the field of endodontics and his commitment to strengthening relationships within the industry align perfectly with Odne Inc.’s mission,” adds Dr. Andreas Schmocker, CEO/Founder. “His extensive background in KOL development underscores his ability to drive strategic initiatives and build networks of influence that will contribute to the company’s growth and success. Joe’s understanding of the DSO market positions Odne Inc. to effectively navigate this rapidly evolving field.”
Odne’s Priority Access Program (PAP) will allow a select group of endodontic specialists to gain first access to the clinical use of Odne’s innovative technology platform for root canal obturation: OdneFill and OdneCure. Priority Access Program Associates will form the core of Odne’s scientific community, transforming endodontics. A PAP initiative is to conduct a clinical case registry, gathering further scientific knowledge about the clinical use of Odne’s devices.
OdneFill is the first FDA-cleared light-curing, injectable endodontic obturation material. OdneFill is a hydrogel, a class of biomaterials known for their excellent biocompatibility and hydrophilicity. Due to its water-like viscosity and extremely high hydrophilicity in its uncured state, it can flow into complex endodontic structures such as isthmuses, deltas, C-shaped canals. After curing with OdneCure, the corresponding microlaser polymerization device, it provides root canal sealing without gap and long-term occlusion.
“We are excited to present our innovative Root Preservation Therapy at the AAE Annual Meeting to the endodontic community for the first time,” adds Holger Essig, GM Global Marketing. “The majority of Odne’s Swiss R&D and Product Management team will be present to train on the clinical application of our game-changing technology platform. The support we’ve received from our KOLs, partners and investors and the intranet community’s interest in the Priority Access Program has been amazing. We are very grateful for the support we are receiving in endo’s transformation.”
About Odne
Odne AG (formerly Lumendo AG), has its roots in a pioneering collaboration between two renowned Swiss institutions: the Swiss Federal Institutes of Technology in Lausanne and Zurich (EPFL & ETH Zürich). Founded in 2018, Odne’s journey began by licensing cutting-edge technology assets from these esteemed institutes.
Odne is committed to pioneering the future of endodontics through advanced technology and innovative solutions. Endodontics, the branch of dentistry that deals with root canal treatments, has been marred by complexity and unpredictability. Odne is on a mission to change that.
Root canal treatments have long posed challenges for dentists, with traditionally low success rates ranging from 46% to 91%. With more than 60 million annual treatments worldwide, these failures result in significant healthcare costs. Odne’s technology platform addresses these issues by offering treatment options for both dentists and their patients. Scheduled to launch in the US in 2024, Odne’s medical device portfolio addresses issues such as cleaning and obturation of complex root canal morphologies. Odne Inc., USA was founded to serve the needs of the US endodontic market and leads the market.
Odne is backed by venture capital funds focused on the health and dental industry. Recently, Revere Partner (NY), an independent venture fund providing capital for cutting-edge innovations in oral and systemic health, and NV Capital (LIE), a family-owned venture capital boutique led the Series A1 financing. In addition to the main investors, other famous funds such as the Dental Innovation Alliance (DIA), Plug&Play, Hatcher, Züricher Kantonalbank, as well as various family offices and angel investors, support the launch of Odne in the US market.
Disclaimer: Odne Fill and Odne Cure are cleared for use in the US only. All other Odne devices are currently in development and have not received approval for clinical use.
